Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC). The study hypothesizes is that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. The study hypothesizes that combination chemotherapy and radiation is superior to radiation alone in inducing a biological response. A biological response, or change in the tumor microenvironment (TME), is defined by reduced infiltration of intra-tumoral regulatory T cells (Tregs

Trial Details

NCT ID
NCT07027436
Phase
PHASE3
Sponsor
Hamilton Health Sciences Corporation
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Chemotherapy/Radiation
Locations (sample)
  • Hamilton, Ontario, Canada|43.25011,-79.84963
  • London, Ontario, Canada|42.98339,-81.23304

Key Eligibility Criteria

  • Radiologically or biopsy proven solitary HCC without biliary invasion or metastases, Liver Imaging Reporting and Data Systems (LI- RADS) 4 or 5 onl…
  • Tumour less than 12 cm in maximum size on CT or MRI.
  • Planned surgical resection of HCC with a life expectancy of at least 12 weeks
  • Age \>18 years at time of study entry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →